Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omr-IgG-am (OMRIX Biopharmaceuticals, Inc.)
- Development stage
- Discontinued
- Lead developer
- OMRIX Biopharmaceuticals
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Omr-IgG-am is an intravenous immunoglobulin (IVIg) therapy containing high titers of neutralizing antibodies against the West Nile virus (WNV). Developed by Omrix Biopharmaceuticals in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the product is derived from pooled human plasma of donors in Israel, where WNV is endemic. It was designed to provide passive immunity to patients with, or at high risk for, neuroinvasive West Nile virus disease, such as encephalitis or myelitis. Although evaluated in Phase I/II clinical trials, the therapy did not demonstrate a significant clinical benefit compared to standard IVIg or placebo and is not currently approved for use in the United States.
- Brand names
- Omr-IgG-am
- Other names
- Omr-IgG-am 5%West Nile Virus Intravenous Immunoglobulin
02
Targets
WNV E (West Nile virus envelope protein)
Beyond the preview
Go deeper on Omr-IgG-am (OMRIX Biopharmaceuticals, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omr-IgG-am (OMRIX Biopharmaceuticals, Inc.).